1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2016

Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2016" provides an overview of Globoid Cell Leukodystrophy (Krabbe Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Globoid Cell Leukodystrophy (Krabbe Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in North America 8
Clinical Trials by G7 Countries: Proportion of Globoid Cell Leukodystrophy (Krabbe Disease) to Central Nervous System Clinical Trials 9
Clinical Trials in G7 Countries by Trial Status 10
Clinical Trials by Phase 11
In Progress Trials by Phase 12
Clinical Trials by Trial Status 13
Clinical Trials by End Point Status 14
Subjects Recruited Over a Period of Time 15
Clinical Trials by Sponsor Type 16
Prominent Sponsors 17
Top Companies Participating in Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials 18
Prominent Drugs 19
Clinical Trial Profile Snapshots 20
Appendix 34
Abbreviations 34
Definitions 34
Research Methodology 35
Secondary Research 35
About GlobalData 36
Contact Us 36
Disclaimer 36
Source 37

List of Tables
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials by Region, 2016* 5
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016* 8
Proportion of Globoid Cell Leukodystrophy (Krabbe Disease) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 9
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 10
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials by Phase, 2016* 11
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 12
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 13
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 14
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 15
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 16
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 17
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 18
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 19

List of Figures
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Proportion of Globoid Cell Leukodystrophy (Krabbe Disease) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 9
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 10
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 11
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 12
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 13
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 14
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 15
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 16
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 17
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 18
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 19
GlobalData Methodology 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Myasthenia Gravis-Market Insights, Epidemiology and Market Forecast-2023

Myasthenia Gravis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Myasthenia Gravis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.